Evenity (Romosozumab) and Rosuvastatin Interaction: Safety, Risks, and Monitoring
At a glance
- Pharmacokinetic interaction / Not expected. Romosozumab is a monoclonal antibody cleared by proteolysis, not by CYP enzymes or drug transporters.
- Romosozumab (Evenity) / Anti-sclerostin monoclonal antibody, FDA-approved for osteoporosis in postmenopausal women at high fracture risk, given as 210 mg subcutaneously once monthly for 12 doses.
- Rosuvastatin (Crestor) / HMG-CoA reductase inhibitor (statin), metabolized in small part by CYP2C9, taken up hepatically via OATP1B1/OATP1B3 transporters.
- FDA boxed warning / Romosozumab may increase risk of myocardial infarction, stroke, and cardiovascular death; contraindicated in patients with MI or stroke in the prior year.
- Why co-prescribing comes up / Romosozumab candidates are often older adults with cardiovascular risk factors already on a statin; the two drugs are frequently used together, not because they interact, but because the patient population overlaps.
- Shared adverse effect to watch / Both drugs are associated with muscle or joint pain, so new myalgia during concurrent use deserves a specific work-up rather than a shrug.
The direct answer
Romosozumab and rosuvastatin do not interact through drug metabolism. Romosozumab is degraded by normal protein catabolism, the same route as other therapeutic monoclonal antibodies, and it does not affect the CYP450 enzymes, P-glycoprotein, or the OATP1B1/OATP1B3 transporters that govern rosuvastatin's hepatic uptake and clearance. This is consistent with the FDA prescribing information for both drugs, and no dose adjustment of either agent is required based on pharmacokinetics alone (FDA Evenity label, 2019; FDA Crestor label, 2023). The consideration that actually deserves a clinical conversation is pharmacodynamic and population-level, not pharmacokinetic: romosozumab carries a boxed warning for myocardial infarction, stroke, and cardiovascular death, and the population prescribed romosozumab, postmenopausal women with severe osteoporosis, frequently already has cardiovascular risk factors that a statin is meant to address. Whether continuing rosuvastatin measurably offsets that boxed-warning risk has not been tested in a dedicated trial; the rationale is plausible pharmacology, not proven benefit.
Why the pathways don't overlap
Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin, a protein secreted by osteocytes that normally restrains bone formation through the Wnt signaling pathway. Like other therapeutic antibodies, it is cleared by proteolytic breakdown into peptides and amino acids rather than by hepatic metabolism. The FDA label for Evenity does not identify formal drug interaction studies, and monoclonal antibodies as a class are not expected to interact with small-molecule drugs through CYP-mediated or transporter-mediated mechanisms, because they simply do not use those pathways (FDA Evenity label, 2019).
Rosuvastatin undergoes limited hepatic biotransformation, with a minor fraction metabolized by CYP2C9. Its hepatic uptake depends heavily on the OATP1B1 and OATP1B3 transporters, which is why drugs that inhibit those transporters (cyclosporine, certain antivirals) can raise rosuvastatin blood levels substantially. Romosozumab has no known effect on OATP transporters or CYP enzymes, so it is not expected to change rosuvastatin exposure (FDA Crestor label, 2023).
The real question: what does the boxed warning mean for a statin user?
Romosozumab carries a boxed warning due to a cardiovascular safety signal that emerged during its pivotal clinical development. The ARCH trial, which evaluated romosozumab followed by alendronate versus alendronate monotherapy in postmenopausal women with osteoporosis and prior fragility fracture, documented a higher incidence of adjudicated major adverse cardiovascular events in romosozumab-treated participants compared to those receiving alendronate alone over the initial 12 months of treatment. Following FDA review of this imbalance, a boxed warning was incorporated that recommends against romosozumab use in patients who have experienced myocardial infarction or stroke in the past year (FDA Evenity label, 2019). Readers should verify specific event rates reported in secondary sources against the most current FDA label, as safety information and label language may be updated through subsequent supplements.
A separate placebo-controlled trial of romosozumab (FRAME) did not show the same cardiovascular imbalance, which has fueled discussion about whether alendronate itself was mildly protective in ARCH rather than romosozumab being independently harmful, or whether the signal reflects chance in a comparator-dependent trial. This remains an open question in the literature and is not resolved by the FDA label alone; readers who need the precise trial-level data should consult the primary ARCH and FRAME publications directly rather than rely on a secondhand percentage.
Because of this uncertainty, professional guidelines generally frame the romosozumab decision as an individualized risk-benefit judgment for patients with elevated fracture risk who also carry cardiovascular risk factors, rather than an absolute contraindication outside the boxed-warning exclusion (recent MI or stroke). Cardiovascular risk assessment and optimization of modifiable risk factors, which includes statin therapy where indicated, before starting romosozumab is a reasonable and guideline-consistent step, though it is site judgment to say a statin will specifically counteract the ARCH signal, since that has not been tested in a trial designed for that purpose.
Should a patient stop their statin before starting romosozumab?
No available evidence supports stopping a statin to accommodate romosozumab. Rosuvastatin lowers LDL cholesterol and reduces cardiovascular event rates in appropriately selected patients, which is the opposite of what a patient with an elevated cardiovascular risk profile needs while starting a drug that carries a cardiovascular boxed warning. Stopping the statin would remove an established protective therapy without any pharmacologic reason tied to romosozumab itself. The decision to start, continue, or intensify statin therapy should be based on the patient's independent cardiovascular risk profile and standard lipid-management guidelines, not on the presence or absence of romosozumab.
There is a plausible, mechanistically coherent hypothesis that statins' anti-inflammatory and plaque-stabilizing effects could be relevant given that sclerostin (romosozumab's target) has been described in vascular tissue as well as bone in some research. This is a mechanistic hypothesis, not an established clinical benefit, and it has not been confirmed by a trial that specifically tested statin co-therapy as a mitigator of romosozumab's cardiovascular signal. Treat it as a rationale for not discontinuing a statin, not as a reason to start one solely because a patient is receiving romosozumab.
Monitoring when both drugs are used together
Muscle symptoms. Romosozumab is associated with arthralgia and myalgia in clinical trials. Statins, including rosuvastatin, are associated with myalgia and, rarely, more serious myopathy or rhabdomyolysis. When a patient on both drugs reports new muscle pain, the practical step is a creatine kinase (CK) level rather than assuming which drug is responsible. A CK that is markedly elevated points toward statin-associated myopathy and warrants statin dose reduction or interruption per standard statin safety practice; a normal CK with joint-predominant pain is more consistent with romosozumab's arthralgic profile, which typically resolves without stopping treatment. Individualized dosing decisions should be made by the treating clinician, not by this article.
Cardiovascular symptom screening. At each monthly romosozumab injection visit, ask about new chest pain, exertional dyspnea, or transient neurologic symptoms. The FDA label recommends discontinuing romosozumab if a myocardial infarction or stroke occurs during treatment (FDA Evenity label, 2019).
Serum calcium. Romosozumab can cause hypocalcemia, and the FDA label calls for adequate calcium and vitamin D intake before and during treatment, with particular caution in renal impairment (FDA Evenity label, 2019). Rosuvastatin does not affect calcium metabolism, but the monthly injection visit is a convenient point to confirm supplementation adherence.
Lipid panel and hepatic monitoring for rosuvastatin. Standard statin practice includes confirming LDL response after starting or adjusting rosuvastatin and checking liver enzymes at baseline and as clinically indicated (FDA Crestor label, 2023). These are unaffected by concurrent romosozumab use.
Renal function. Rosuvastatin's higher doses are restricted in significant renal impairment, and romosozumab-associated hypocalcemia can be more pronounced when renal clearance of phosphate is reduced. Neither issue reflects a drug-drug interaction; both reflect the need for renal-function-aware dosing of each drug independently, especially in older adults (FDA Crestor label, 2023; FDA Evenity label, 2019).
Evidence-status map: romosozumab plus rosuvastatin
| Claim | Status | What this means for practice |
|---|---|---|
| No pharmacokinetic interaction (no shared CYP, P-gp, or OATP pathway) | Established, based on FDA labeling and known clearance mechanisms of monoclonal antibodies versus statins | No dose adjustment of either drug needed for this reason |
| Romosozumab carries an FDA boxed warning for MI, stroke, and cardiovascular death | Established, FDA label | Screen for recent MI/stroke before prescribing; screen for cardiac symptoms during treatment |
| A cardiovascular imbalance was seen in the active-comparator ARCH trial but not in the placebo-controlled FRAME trial | Established as a documented discrepancy; the explanation is unresolved | Do not treat the exact percentage difference as settled without checking the primary trial publications or current FDA label |
| Continuing a statin during romosozumab therapy is reasonable cardiovascular risk management | Plausible and consistent with general cardiovascular risk-reduction principles | Do not stop a statin because a patient is starting romosozumab |
| A statin specifically mitigates romosozumab's cardiovascular signal | Not established; no dedicated trial has tested this | Do not tell a patient the statin "protects them from Evenity's risk" as a proven fact |
| Sclerostin inhibition affects vascular tissue in a way relevant to cardiovascular risk | Mechanistically plausible, based on early research describing sclerostin in vascular tissue | Present as hypothesis, not mechanism of harm confirmed in humans |
| New muscle pain during combined use should prompt a CK check rather than an assumption | Site judgment, consistent with standard statin myopathy work-up | Use CK to differentiate statin myopathy from romosozumab arthralgia before adjusting either drug |
| Statins improve bone mineral density enough to matter clinically | Not established; observational data are inconsistent and no statin is approved for this use | Do not substitute a statin for an osteoporosis therapy |
What this does not establish
This combination has not been studied in a dedicated interaction trial, and no professional guideline frames rosuvastatin as either a required or forbidden co-medication during romosozumab therapy. The absence of a described pharmacokinetic interaction is a mechanistic and regulatory-labeling conclusion, not proof from a head-to-head interaction study. The cardiovascular rationale for continuing a statin is sound as general cardiology practice, but it is not validated as a specific countermeasure to romosozumab's boxed warning. Anyone relying on exact trial percentages for ARCH or FRAME, or on specific hazard ratios from rosuvastatin cardiovascular outcome trials, should verify those figures against the primary trial publications or the current FDA labels rather than a secondary summary, including this one.
When to seek urgent care
New chest pain, one-sided weakness, slurred speech, sudden severe headache, or vision changes during romosozumab treatment warrant emergency evaluation, since these can signal the cardiovascular events the boxed warning addresses. Dark urine, severe muscle pain, or marked weakness in a patient on rosuvastatin warrants prompt medical evaluation for possible statin myopathy or rhabdomyolysis. Neither symptom pattern should be managed by adjusting medication without clinical assessment.
Frequently asked questions
Can I take Evenity (romosozumab) with rosuvastatin?
Is it safe to combine Evenity and rosuvastatin?
Does romosozumab change how rosuvastatin works?
Should I stop my statin before starting Evenity?
Can both romosozumab and rosuvastatin cause muscle pain?
What cardiovascular monitoring is recommended during romosozumab therapy?
Does rosuvastatin protect bone density?
Do I need blood tests while taking both medications?
References
- Amgen Inc. Evenity (romosozumab-aqqg) prescribing information. U.S. Food and Drug Administration, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
- AstraZeneca. Crestor (rosuvastatin calcium) prescribing information. U.S. Food and Drug Administration, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021366s045lbl.pdf
- Merck & Co. Fosamax (alendronate sodium) prescribing information. U.S. Food and Drug Administration, 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf
Note for editorial and clinical review: earlier drafts of this page cited specific trial percentages (ARCH, FRAME, JUPITER) and journal articles by PMID. Those identifiers could not be verified against the primary literature during this revision and have been removed or replaced with hedged, non-numeric language. Before publication, a reviewer with access to the primary ARCH, FRAME, and JUPITER publications should confirm any specific effect sizes that are reinstated, and confirm current FDA label language for both drugs.